This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Diabetes Mellitus, Type 2 or Adult
and you are
between 18 and 65
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is a Phase 1 randomized, double-blind, sponsor open, 4 arm, 2 way cross-over study using 2 cohorts. The objective of the study is to evaluate the pharmacodynamics (PD) effects and the pharmacokinetic (PK) of single day dosing of 2 mg and 4 mg doses of ertugliflozin (Ertu, PF-04971729/MK-8835) each administered once vs twice daily (morning [AM] and evening [PM]) in adults with type 2 diabetes.

Provided treatments

  • Drug: Ertugliflozin 2 mg single dose
  • Drug: Ertugliflozin 2 mg split into twice daily
  • Drug: Ertugliflozin 4 mg single dose
  • Drug: Ertugliflozin 4 mg split into twice daily
  • Drug: Placebo

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01054300. The sponsor of the trial is Merck Sharp & Dohme Corp. and it is looking for 52 volunteers for the current phase.
Official trial title:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Single Day Evaluation Of The Pharmacokinetic-Pharmacodynamic Effect Of Once And Twice Daily Oral Administration Of PF-04971729 In Patients With Type 2 Diabetes Mellitus